Obesity
Study
Phase 3 studies; findings remain population- and protocol-specific.1
Metabolic
Survodutide
GLP-1/glucagon receptor dual agonist (BI 456906)
Investigational survodutide; no FDA-approved product verified.
What does it do?
Molecular information
3Amino-acid sequence
An exact sequence has not been verified for this formulation.
LengthNot independently verified
Molecular weight · DaNot independently verified for the exact supplied form
Molecular formulaNot independently verified for the exact supplied form3
Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life6.5 days8
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 32.5 d
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Phase 2 Clinical Trial Data (Boehringer Ingelheim)
Source’s reported peak time: 2 days. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Published phase 3 weight result
Mean weight change at 76 weeks was −13.0% with 6 mg versus −5.4% with placebo in adults without diabetes (treatment-regimen estimand).1
Additional 2026 diabetes-population trial
A separate phase 3 publication evaluates weekly 3.6 or 6.0 mg in adults with type 2 diabetes and BMI at least 27. It is a different population from SYNCHRONIZE-1.2
Reported timelines
Reference & communitySource expectations
GI/appetite changes weeks 1–4; weight change weeks 4–24+, with trial outcomes assessed around week 46. Not individual forecasts.9
These are reported timelines, not a prediction of your response.
Doses & schedules
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 3.6 mg target | Once weekly | SYNCHRONIZE-1 obesity trial725 adults with obesity without diabetesHuman study | 76 weeks | 1 |
Population 725 adults with obesity without diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 3.6 or 6.0 mg target | |||||
| SubQSubcutaneous | 6 mg target | Once weekly | SYNCHRONIZE-1 obesity trial725 adults with obesity without diabetesHuman study | 76 weeks | 1 |
Population 725 adults with obesity without diabetes Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 3.6 or 6.0 mg target | |||||
| SubQ | 0.6 mg titrated over 24 weeksStarting dose | Once weekly with 4-week intervals | Obesity - Conservative StartReference report | Long-term therapy - trials up to 76 weeks, likely continuous use | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Week16–24 “steady state” claim is not a PK calculation; source combination labels do not establish safety. Source tabs Injectable | |||||
| SubQSubQ (abdomen/thigh) | 3.6-6.0 mg | Once weekly | Obesity - Standard ProtocolReference report | Long-term therapy - trials up to 76 weeks, likely continuous use | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Week16–24 “steady state” claim is not a PK calculation; source combination labels do not establish safety. Source tabs Injectable | |||||
| SubQ | 2.4-4.8 mg | Once weekly | MASH TreatmentReference report | Long-term therapy - trials up to 76 weeks, likely continuous use | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Week16–24 “steady state” claim is not a PK calculation; source combination labels do not establish safety. Source tabs Injectable | |||||
| SubQ | 0.3-2.7 mg | Once weekly | Type 2 DiabetesReference report | Long-term therapy - trials up to 76 weeks, likely continuous use | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Week16–24 “steady state” claim is not a PK calculation; source combination labels do not establish safety. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Long-term therapy - trials up to 76 weeks, likely continuous use
- Break
- No cycling required - continuous weekly therapy
Reported timing
Any time of day, with or without food - maintain consistent weekly schedule
Side effects & safety
Frequent GI adverse events
GI symptoms occurred in 80.9% and 89.7% of the two survodutide groups, versus 47.9% with placebo.
1Common
Nausea, vomiting, diarrhea and heart-rate elevation.
Urgent
Persistent GI symptoms/dehydration, severe abdominal/back or RUQ pain, hypoglycemia, allergy or arrhythmia.
Unknowns
Pregnancy/breastfeeding and combination safety uncertain; organ-impairment claims require trial context.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Semaglutide / tirzepatide
Caution reportedOverlapping GLP-1 signaling.9
Reference report · Pep-Pedia label: Use CautionSulfonylureas
Caution reportedHypoglycemia.9
Reference report · Pep-Pedia label: Monitor CombinationOral contraceptives
Caution reportedOne-hour source rule unverified.9
Reference report · Pep-Pedia label: Requires TimingWarfarin
Caution reportedPotential INR/absorption changes.9
Reference report · Pep-Pedia label: Monitor CombinationOther glucagon agonists
Avoidance reportedReceptor duplication.9
Reference report · Pep-Pedia label: Avoid CombinationMetformin
Unverified pairingBackground trial therapy.9
Reference report · Pep-Pedia label: CompatibleSGLT2 inhibitors
Unverified pairingPermitted trial co-treatment.9
Reference report · Pep-Pedia label: CompatibleInsulin
Unverified pairingGlucose effects require assessment.9
Reference report · Evidence context: Dose dependentOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- The source specifies refrigeration after preparation.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceClear to slightly opalescent solutionReported appearanceSealed vial with intact rubber stopperReported appearanceWithin expiration dateReported variationSlight foam after reconstitutionReported concernCloudy solution or visible particlesReported concernDiscoloration of powder or solution
9Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
9Refrigerate at 2-8°C, protect from light, use within 4 weeks of reconstitution
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Research-market product identity, purity and formulation cannot be established from a publication.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsSource context
Week16–24 “steady state” claim is not a PK calculation; source combination labels do not establish safety.
Compound identity & other names
An investigational dual receptor agonist with published obesity and liver-disease trials. New phase 3 data are reported with the study population and estimand.
Investigational survodutide; no FDA-approved product verified.
GLP-1/glucagon receptor dual agonist (BI 456906)3
How it may work
Combines appetite/glucose effects with glucagon-related energy and liver-fat metabolism.9
Published phase 3 weight result
Mean weight change at 76 weeks was −13.0% with 6 mg versus −5.4% with placebo in adults without diabetes (treatment-regimen estimand).
1Additional 2026 diabetes-population trial
A separate phase 3 publication evaluates weekly 3.6 or 6.0 mg in adults with type 2 diabetes and BMI at least 27. It is a different population from SYNCHRONIZE-1.
2Research areas and evidence gaps
Obesity research. Phase 3 studies; findings remain population- and protocol-specific.1
- Research-market product identity, purity and formulation cannot be established from a publication.
Additional uses listed by Pep-Pedia
Weight. Obesity with or without diabetes and maintenance.9
Metabolic / liver. MASH, liver fat and glycemic control.9
Cardiovascular. BP, lipids and other risk markers; clinical outcome benefit requires separate evidence.9
Community reports Unvalidated
Weight discussions as described by Pep-Pedia.3
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- survodutide 2026 phase 3 study site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “203 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1SYNCHRONIZE-1: survodutide once weekly in adults with obesityAbstract checked
AI-PREPARED SUMMARY
2026 phase 3 trial in 725 adults without diabetes: mean change at 76 weeks −12.2% (3.6 mg), −13.0% (6 mg), and −5.4% placebo under the treatment-regimen estimand.
Published phase 3 weight result
Mean weight change at 76 weeks was −13.0% with 6 mg versus −5.4% with placebo in adults without diabetes (treatment-regimen estimand).
Additional research · Checked 2026-10-12
2Survodutide in adults with obesity and type 2 diabetesAbstract checked
AI-PREPARED SUMMARY
2026 publication reports a phase 3 trial in adults with obesity and diabetes; the abstract reports greater weight reduction than placebo.
Additional 2026 diabetes-population trial
A separate phase 3 publication evaluates weekly 3.6 or 6.0 mg in adults with type 2 diabetes and BMI at least 27. It is a different population from SYNCHRONIZE-1.
Additional research · Checked 2026-10-12
3Pep-Pedia: Survodutide — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
4Phase 2 Obesity Trial Without Diabetes (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The obesity trial reportedly found 14.9% mean weight loss at 4.8 mg versus 2.8% on placebo over 46 weeks.
Reported population / model
Human
Reported study details
0.6-4.8mg weekly · 46 weeks · Up to 14.9% weight loss
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Phase 2 MASH and Fibrosis Trial (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: MASH improvement without worse fibrosis occurred in 43–62% across dose groups versus 14% with placebo; responses were not simply dose-proportional.
Reported population / model
Human
Reported study details
2.4-6.0mg weekly · 48 weeks · 47-62% MASH improvement
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Phase 2 Type 2 Diabetes Trial (2023)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports greater short-term weight loss than semaglutide 1 mg in diabetes; this does not compare against obesity-dose semaglutide.
Reported population / model
Human
Reported study details
0.3-2.7mg weekly · 16 weeks · Superior to semaglutide
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Preclinical Pharmacology Study (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Laboratory receptor activity and animal half-lives supported development; mouse and dog elimination values are not human dosing evidence.
Reported population / model
Animal/In vitro
Reported study details
Various doses · EC50 0.52nM GCGR, 0.33nM GLP-1R
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pep-Pedia: Survodutide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 6.5 days and a peak time of 2 days. Stated attribution: Phase 2 Clinical Trial Data (Boehringer Ingelheim). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
9Pep-Pedia: Survodutide — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12